CJC/Ipamorelin — Spray

Product classification

CJC/Ipamorelin 5mg/5mg is a dual-compound research preparation containing two distinct synthetic research compounds. It is not a single molecular entity and does not have a single molecular formula, molecular weight, or CAS number.

CJC component — scientific identity

CJC-1295 without DAC, also designated Modified GRF (1-29) (CAS 446036-97-1; PubChem CID 91976842), is a synthetic 29-amino-acid analogue of GHRH(1-29) incorporating four amino acid substitutions relative to the native sequence — D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ — that confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage at the native Tyr-Ala N-terminal bond while preserving full GHRHR agonist activity. Molecular formula C₁₅₂H₂₅₂N₄₄O₄₂; molecular weight approximately 3,367.9 g/mol. Stated quantity: 5mg per bottle.

Ipamorelin component — scientific identity. Ipamorelin (CAS 170851-70-4; PubChem CID 9831659), first characterized at Novo Nordisk under development code NNC 26-0161, is a synthetic pentapeptide with the sequence H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂. The sequence incorporates alpha-aminoisobutyric acid (Aib) at the N-terminus, D-2-naphthylalanine at position 3, D-phenylalanine at position 4, and a C-terminal primary amide — non-proteinogenic residues that confer GHS-R1a selectivity and proteolytic stability. Molecular formula C₃₈H₄₉N₉O₅; molecular weight 711.9 g/mol. Stated quantity: 5mg per bottle.

Mechanistic distinction

The two components are pharmacologically non-competing and engage entirely distinct receptor populations. CJC-1295 without DAC targets GHRHR — a Class B GPCR — activating the Gs/adenylyl cyclase/cAMP intracellular cascade. Ipamorelin targets GHS-R1a — a Class A GPCR — activating the Gq/phospholipase C/PKC cascade. Both receptors are expressed on pituitary somatotrophs, providing the scientific basis for dual-pathway experimental designs.

CJC variant distinction

CJC-1295 without DAC (CAS 446036-97-1, ~3,368 g/mol, 29 residues) is analytically distinguishable from CJC-1295 with DAC (CAS 446262-90-4, ~3,647 g/mol, 30 residues) by a ~279 Da mass difference on mass spectrometric confirmation. Human clinical pharmacology data from Teichman et al. (2006) applies specifically to the DAC form and should not be attributed to this compound.

Product content

5mg CJC-1295 without DAC and 5mg Ipamorelin per bottle; 45 sprays per bottle. Per-spray quantity for each component is documented on the product label and batch Certificate of Analysis.

Physical form: Liquid research spray.

Purity: Research-grade.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering identity and purity confirmation for both components individually, and lot traceability. The CJC component molecular weight confirmation on the COA simultaneously confirms the No DAC form.

Research-use classification

Research Use Only. Neither component holds regulatory approval for human or veterinary use in any jurisdiction. Not intended for administration to humans or animals.

GHRH biology and CJC-1295 without DAC

Growth hormone-releasing hormone (GHRH) is the primary stimulatory hypothalamic regulator of GH secretion from pituitary somatotrophs. GHRH(1-29) is the minimal biologically active fragment; it binds GHRHR, activating Gs and adenylyl cyclase, increasing intracellular cAMP, and driving acute GH secretion from somatotroph cells. Native GHRH is rapidly inactivated in circulation — functional half-life approximately 7 minutes — by DPP-IV cleavage at the Tyr-Ala N-terminal bond. CJC-1295 without DAC addresses this limitation with D-Ala at position 2, eliminating the DPP-IV scissile site without altering receptor contact residues and extending the functional half-life to approximately 30 minutes while preserving full GHRHR agonist activity. In primary rat anterior pituitary cell preparations, Modified GRF (1-29) stimulates GH secretion in a concentration-dependent manner consistent with GHRHR pharmacology. Its ~30-minute pulsatile pharmacokinetic profile — contrasting with the ~6–8 day half-life of the DAC-containing form — makes it experimentally appropriate for co-administration with short-acting secretagogues such as Ipamorelin in pulsatile GH-axis research designs.

Ipamorelin and GHS-R1a signaling research

Ipamorelin was first characterized by Raun and colleagues (European Journal of Endocrinology, 1998; PMID 9849822) at Novo Nordisk. In preclinical studies, Ipamorelin produced GH release in rat models comparable in amplitude to other GH secretagogue compounds while showing substantially lower stimulation of cortisol, prolactin, and ACTH — a selectivity profile distinguishing it from earlier GHRP-class compounds and representing the principal focus of its pharmacology research. Johansen and colleagues (Growth Hormone and IGF Research, 1999) examined Ipamorelin in rodent bone and GH pulsatility models. Human pharmacokinetic-pharmacodynamic modeling was published by Gobburu and colleagues (Pharmaceutical Research, 1999; PMID 10496658). A Phase 2 clinical study by Beck and colleagues (Diseases of the Colon and Rectum, 2014) examined Ipamorelin in a postoperative gastrointestinal context in human subjects — providing human pharmacological data outside the GH-axis indication. These findings are model-specific and compound-specific.

The dual-receptor research rationale

GHRHR and GHS-R1a are distinct receptor populations on pituitary somatotrophs activating non-competing intracellular cascades. Their simultaneous activation has been studied in preclinical research as a method for examining additive or potentiating effects on GH pulse amplitude. Alba and colleagues (American Journal of Physiology — Endocrinology and Metabolism, 2006; PMID 16849629) examined combined GHRH analogue plus GHS agonist administration in GH-deficient animal models, reporting greater IGF-1 restoration with dual-pathway stimulation than with either compound alone in those specific preclinical systems. Ionescu and Frohman (JCEM, 2006) examined pulsatile GH secretion during GHRH axis stimulation, providing context for pulsatility preservation rationale in combination experimental designs. These are preclinical animal model findings and do not establish human clinical efficacy for the CJC/Ipamorelin combination.

Published evidence status and regulatory context

The published research record for each component independently is substantive. Published research specifically evaluating the CJC-1295 without DAC and Ipamorelin combination as a defined experimental pairing is limited in peer-reviewed literature relative to the individual compounds; researchers should not interpret individual-compound evidence as establishing the combination's efficacy or safety in humans. No published human clinical trial of CJC-1295 without DAC as a standalone compound has been identified — human clinical evidence in the CJC-1295 literature relates to the DAC-containing form. Neither compound individually nor the CJC/Ipamorelin combination holds regulatory approval for any human indication in any jurisdiction.

For a dual-peptide research spray, analytical documentation must address each component independently. CJC-1295 without DAC (~3,368 g/mol) and Ipamorelin (~711.9 g/mol) have substantially different molecular weights, meaning mass spectrometric confirmation readily resolves both compounds and confirms that the supplied material contains both the GHRH analogue and the secretagogue at their specified identities.

Identity confirmation: Each production lot is characterised by mass spectrometric analysis for both components, verifying that the observed molecular ions are consistent with CJC-1295 without DAC (C₁₅₂H₂₅₂N₄₄O₄₂, approximately 3,367.9 g/mol) and Ipamorelin (C₃₈H₄₉N₉O₅, 711.9 g/mol). This simultaneously confirms that the CJC component is the No DAC form — distinguishable from CJC-1295 with DAC at ~3,647 g/mol by the ~279 Da mass difference.

Purity assessment: Chromatographic purity analysis quantifies each target compound relative to other UV-absorbing species in the chromatogram, confirming the integrity of both components.

Batch traceability and Certificate of Analysis: Every production lot of CJC/Ipamorelin 5mg/5mg spray is traceable to a specific batch. A batch-specific Certificate of Analysis is accessible on the Longevia Research website, covering identity, purity, and lot information for both components. Researchers are encouraged to review the batch documentation — particularly the CJC component molecular weight confirmation — before incorporating the material into experimental protocols.

Storage: Specific storage conditions for this lot are confirmed on the batch Certificate of Analysis and product labelling.

Longevia Research supplies CJC/Ipamorelin 5mg/5mg Spray for laboratory and in-vitro research use only. The product is intended for qualified researchers and trained laboratory personnel working in appropriate controlled research environments.

CJC/Ipamorelin is a dual-compound synthetic research product supplied strictly as a laboratory research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. Neither CJC-1295 without DAC nor Ipamorelin holds regulatory approval for human or veterinary therapeutic use in any jurisdiction, and Longevia does not supply this product for administration to humans or animals, for clinical diagnostics, or for any therapeutic application.

No therapeutic, diagnostic, or efficacy claims are made for this product or its individual components. The preclinical and pharmacological literature referenced on this page describes experimental observations from defined cell-based and animal model systems. Evidence for each individual compound does not constitute evidence for the combination product. No dosing instructions, spray-frequency guidance, administration protocols, or cycle recommendations are provided. The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations.